The role of alterations in permeability of the intestinal mucosa in the genesis of functional gastrointestinal disorders
- Authors: Andreev D.N.1
-
Affiliations:
- Yevdokimov Moscow State University of Medicine and Dentistry
- Issue: Vol 21, No 8 (2019)
- Pages: 29-34
- Section: Articles
- URL: https://ogarev-online.ru/2075-1753/article/view/96779
- DOI: https://doi.org/10.26442/20751753.2019.8.190539
- ID: 96779
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
Dmitrii N. Andreev
Yevdokimov Moscow State University of Medicine and Dentistry
Email: dna-mit8@mail.ru
Cand. Sci. (Med.) Moscow, Russia
References
- Drossman D.A, Hasler W.L. Rome IV-Functional GI Disorders: Disorders of Gut-Brain Interaction. Gastroenterology 2016; 150 (6): 1257-61.
- Андреев Д.Н., Заборовский А.В., Трухманов А.С. и др. Эволюция представлений о функциональных заболеваниях желудочно-кишечного тракта в свете Римских критериев IV пересмотра (2016 г.). РЖГГК. 2017; 1: 4-11. @@Andreev D.N., Zaborovskii A.V., Trukhmanov A.S. et al. Evoliutsiia predstavlenii o funktsional'nykh zabolevaniiakh zheludochno-kishechnogo trakta v svete Rimskikh kriteriev IV peresmotra (2016 g.). RZhGGK. 2017; 1: 4-11 (in Russian).]
- De Bortoli N, Tolone S, Frazzoni M et al. Gastroesophageal reflux disease, functional dyspepsia and irritable bowel syndrome: common overlapping gastrointestinal disorders. Ann Gastroenterol 2018; 31 (6): 639-48.
- Von Wulffen M, Talley N.J, Hammer J et al. Overlap of Irritable Bowel Syndrome and Functional Dyspepsia in the Clinical Setting: Prevalence and Risk Factors. Dig Dis Sci 2019; 64 (2): 480-6.
- Ford A.C, Marwaha A, Lim A, Moayyedi P. Systematic review and meta-analysis of the prevalence of irritable bowel syndrome in individuals with dyspepsia. Clin Gastroenterol Hepatol 2010; 8 (5): 401-9.
- Choung R.S. Natural history and overlap of functional gastrointestinal disorders. Korean J Gastroenterol 2012; 60 (6): 345-8.
- Keita Å.V, Söderholm J.D. Mucosal permeability and mast cells as targets for functional gastrointestinal disorders. Curr Opin Pharmacol 2018; 43: 66-71.
- Holtmann G, Shah A, Morrison M. Pathophysiology of Functional Gastrointestinal Disorders: A Holistic Overview. Dig Dis 2017; 35 (Suppl. 1): 5-13.
- Вялов С.С. Нарушение проницаемости слизистой оболочки как фактор патогенеза функциональных нарушений желудочно-кишечного тракта: обоснование и возможности коррекции. Consilium Medicum. 2018; 20 (12): 99-104. doi: 10.26442/20751753.2018.12.180062 @@Vialov S.S. Mucosal permeability disturbances as a pathogenesis factor of gastrointestinal tract functional disorders: rationale and correction possibilities. Consilium Medicum. 2018; 20 (12): 99-104. doi: 10.26442/20751753.2018.12.180062 (in Russian)
- Farré R, Vicario M. Abnormal Barrier Function in Gastrointestinal Disorders. Handb Exp Pharmacol 2017; 239: 193-217.
- Bischoff S.C, Barbara G, Buurman W et al. Intestinal permeability - a new target for disease prevention and therapy. BMC Gastroenterol 2014; 14: 189.
- Pascual S, Martínez J, Pérez-Mateo M. The intestinal barrier: functional disorders in digestive and non-digestive diseases. Gastroenterol Hepatol 2001; 24 (5): 256-67.
- Shen L, Turner J.R. Role of epithelial cells in initiation and propagation of intestinal inflammation. Eliminating the static: tight junction dynamics exposed. Am J Physiol Gastrointest Liver Physiol 2006; 290 (4): G577-82.
- Camara-Lemarroy C.R, Metz L, Meddings J.B et al. The intestinal barrier in multiple sclerosis: implications for pathophysiology and therapeutics. Brain 2018; 141 (7): 1900-16.
- Du L, Kim J.J, Shen J, Dai N. Crosstalk between Inflammation and ROCK/MLCK Signaling Pathways in Gastrointestinal Disorders with Intestinal Hyperpermeability. Gastroenterol Res Pract 2016; 2016: 7374197.
- Bevins C.L, Salzman N.H. Paneth cells, antimicrobial peptides and maintenance of intestinal homeostasis. Nat Rev Microbiol 2011; 9 (5): 356-68.
- Van der Flier L.G, Clevers H. Stem cells, self-renewal, and differentiation in the intestinal epithelium. Annu Rev Physiol 2009; 71: 241-60.
- Zihni C, Mills C, Matter K, Balda M.S. Tight junctions: from simple barriers to multifunctional molecular gates. Nat Rev Mol Cell Biol 2016; 17 (9): 564-80.
- Piche T. Tight junctions and IBS - the link between epithelial permeability, low-grade inflammation, and symptom generation? Neurogastroenterol Motil 2014; 26 (3): 296-302.
- Niessen C.M. Tight junctions/adherens junctions: basic structure and function. J Invest Dermatol 2007; 127 (11): 2525-32.
- Hartsock A, Nelson W.J. Adherens and tight junctions: structure, function and connections to the actin cytoskeleton. Biochim Biophys Acta 2008; 1778 (3): 660-9.
- Hammer A.M, Morris N.L, Earley Z.M, Choudhry M.A. The First Line of Defense: The Effects of Alcohol on Post-Burn Intestinal Barrier, Immune Cells, and Microbiome. Alcohol Res 2015; 37 (2): 209-22.
- Park M.Y, Kim M.Y, Seo Y.R et al. High-fat Diet Accelerates Intestinal Tumorigenesis Through Disrupting Intestinal Cell Membrane Integrity. J Cancer Prev 2016; 21 (2): 95-103.
- Wilcz-Villega E.M, McClean S, O'Sullivan M.A. Mast cell tryptase reduces junctional adhesion molecule-A (JAM-A) expression in intestinal epithelial cells: implications for the mechanisms of barrier dysfunction in irritable bowel syndrome. Am J Gastroenterol 2013; 108 (7): 1140-51.
- Gunnarsson J, Simrén M. Peripheral factors in the pathophysiology of irritable bowel syndrome. Dig Liver Dis 2009; 41: 788-93.
- Camilleri M, Oduyebo I, Halawi H. Chemical and molecular factors in irritable bowel syndrome: current knowledge, challenges, and unanswered questions. Am J Physiol Gastrointest Liver Physiol 2016; 311 (5): G777-G784.
- Ng Q.X, Soh A.Y.S, Loke W et al. The role of inflammation in irritable bowel syndrome (IBS). J Inflamm Res 2018; 11: 345-9.
- Самсонов А.А., Андреев Д.Н., Дичева Д.Т. Синдром раздраженного кишечника с позиций современной гастроэнтерологии. Фарматека. 2014; 18: 7-14. @@Samsonov A.A., Andreev D.N., Dicheva D.T. Sindrom razdrazhennogo kishechnika s pozitsii sovremennoi gastroenterologii. Farmateka. 2014; 18: 7-14 (in Russian)
- Дичева Д.Т., Андреев Д.Н., Щегланова М.П., Парцваниа-Виноградова Е.В. Синдром раздраженного кишечника в свете Римских критериев IV пересмотра (2016 г.). Мед. совет. 2018; 3: 60-6. @@Dicheva D.T., Andreev D.N., Shcheglanova M.P., Partsvania-Vinogradova E.V. Sindrom razdrazhennogo kishechnika v svete Rimskikh kriteriev IV peresmotra (2016 g.). Med. sovet. 2018; 3: 60-6 (in Russian)
- Barbara G, Grover M, Bercik P et al. Rome Foundation Working Team Report on Post-Infection Irritable Bowel Syndrome. Gastroenterology 2019; 156 (1): 46-58.e7.
- Spiller R.C, Jenkins D, Thornley J.P et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 2000; 47: 804.
- Marshall J.K, Thabane M, Garg A.X et al. Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario. Aliment Pharmacol Ther 2004; 20: 1317-22.
- Vazquez-Roque M.I, Camilleri M, Smyrk T et al. Association of HLA-DQ gene with bowel transit, barrier function, and inflammation in irritable bowel syndrome with diarrhea. Am J Physiol Gastrointest Liver Physiol 2012; 303 (11): G1262-9.
- Shulman R.J, Jarrett M.E, Cain K.C et al. Associations among gut permeability, inflammatory markers, and symptoms in patients with irritable bowel syndrome. J Gastroenterol 2014; 49 (11): 1467-76.
- Coëffier M, Gloro R, Boukhettala N et al. Increased proteasome-mediated degradation of occludin in irritable bowel syndrome. Am J Gastroenterol 2010; 105 (5): 1181-8.
- Piche T, Barbara G, Aubert P et al. Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators. Gut 2009; 58 (2): 196-201.
- Bertiaux-Vandaële N, Youmba S.B, Belmonte L et al. The expression and the cellular distribution of the tight junction proteins are altered in irritable bowel syndrome patients with differences according to the disease subtype. Am J Gastroenterol 2011; 106 (12): 2165-73.
- Bonfiglio F, Henström M, Nag A et al. A GWAS meta-analysis from 5 population-based cohorts implicates ion channel genes in the pathogenesis of irritable bowel syndrome. Neurogastroenterol Motil 2018; 30 (9): e13358.
- Chadwick V.S, Chen W, Shu D et al. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology 2002; 122: 1778.
- Liebregts T, Adam B, Bredack C et al. Immune activation in patients with irritable bowel syndrome. Gastroenterology 2007; 132: 913.
- Törnblom H, Lindberg G, Nyberg B, Veress B. Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome. Gastroenterology 2002; 123: 1972.
- Ait-Belgnaoui A, Bradesi S, Fioramonti J et al. Acute stress-induced hypersensitivity to colonic distension depends upon increase in paracellular permeability: role of myosin light chain kinase. Pain 2005; 113 (1-2): 141-7.
- Barbaro M.R, Di Sabatino A, Cremon C et al. Interferon-y is increased in the gut of patients with irritable bowel syndrome and modulates serotonin metabolism. Am J Physiol Gastrointest Liver Physiol 2016; 310 (6): G439-47.
- Chen J, Zhang Y, Deng Z. Imbalanced shift of cytokine expression between T helper 1 and T helper 2 (Th1/Th2) in intestinal mucosa of patients with post-infectious irritable bowel syndrome. BMC Gastroenterol 2012; 12: 91.
- Lee K.N, Lee O.Y. The Role of Mast Cells in Irritable Bowel Syndrome. Gastroenterol Res Pract 2016; 2016: 2031480.
- Guilarte M, Santos J, de Torres I et al. Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum. Gut 2007; 56: 203.
- Barbara G, Stanghellini V, De Giorgio R et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 2004; 126: 693.
- Buhner S, Li Q, Vignali S et al. Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome. Gastroenterology 2009; 137 (4): 1425-34.
- Barbara G, Wang B, Stanghellini V et al. Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology 2007; 132 (1): 26-37.
- Schemann M, Camilleri M. Functions and imaging of mast cell and neural axis of the gut. Gastroenterology 2013; 144 (4): 698-704.e4.
- Bueno L. Protease activated receptor 2: a new target for IBS treatment. Eur Rev Med Pharmacol Sci 2008; 12 (Suppl. 1): 95.
- Gecse K, Róka R, Ferrier L et al. Increased faecal serine protease activity in diarrhoeic IBS patients: a colonic lumenal factor impairing colonic permeability and sensitivity. Gut 2008; 57: 591.
- Edogawa S, Edwinson A.L, Peters S.A et al. Serine proteases as luminal mediators of intestinal barrier dysfunction and symptom severity in IBS. Gut 2019 Mar 28. pii: gutjnl-2018-317416.
- Liang W.J, Zhang G, Luo H.S et al. Tryptase and Protease-Activated Receptor 2 Expression Levels in Irritable Bowel Syndrome. Gut Liver 2016; 10 (3): 382-90.
- Du L, Long Y, Kim J.J et al. Protease Activated Receptor-2 Induces Immune Activation and Visceral Hypersensitivity in Post-infectious Irritable Bowel Syndrome Mice. Dig Dis Sci. 2019; 64 (3): 729-739.
- Stanghellini V, Chan F.K, Hasler W.L et al. Gastroduodenal Disorders. Gastroenterology 2016; 150 (6): 1380-92.
- Маев И.В., Андреев Д.Н., Кучерявый Ю.А. Функциональная диспепсия. М.: Ремедиум, 2019. @@Maev I.V., Andreev D.N., Kucheriavyi Iu.A. Functional dyspepsia. Moscow: Remedium, 2019 (in Russian).]
- Jung H.K, Talley N.J. Role of the Duodenum in the Pathogenesis of Functional Dyspepsia: A Paradigm Shift. J Neurogastroenterol Motil 2018; 24 (3): 345-54.
- Vanheel H, Vicario M, Vanuytsel T et al. Impaired duodenal mucosal integrity and low-grade inflammation in functional dyspepsia. Gut 2014; 63 (2): 262-71.
- Vanheel H, Vicario M, Boesmans W et al. Activation of Eosinophils and Mast Cells in Functional Dyspepsia: an Ultrastructural Evaluation. Sci Rep 2018; 8 (1): 5383.
- Du L, Chen B, Kim J.J et al. Micro-inflammation in functional dyspepsia: A systematic review and meta-analysis. Neurogastroenterol Motil 2018; 30 (4): e13304.
- Маев И.В., Андреев Д.Н., Кучерявый Ю.А. и др. Современные представления о патофизиологических основах синдрома функциональной диспепсии. РЖГГК. 2015; 4: 15-22. @@Maev I.V., Andreev D.N., Kucheriavyi Iu.A.et al. Sovremennye predstavleniia o patofiziologicheskikh osnovakh sindroma funktsional'noi dispepsii. RZhGGK. 2015; 4: 15-22. (in Russian).
- Дичева Д.Т., Субботина Ю.С., Бектемирова Л.Г., Андреев Д.Н. Функциональная диспепсия: от патогенеза к терапевтическим аспектам. Мед. совет. 2019; 3: 18-25. @@Dicheva D.T., Subbotina Iu.S., Bektemirova L.G., Andreev D.N. Funktsional'naia dispepsiia: ot patogeneza k terapevticheskim aspektam. Med. sovet. 2019; 3: 18-25 (in Russian)
- Miwa H, Oshima T, Tomita T et al. Recent understanding of the pathophysiology of functional dyspepsia: role of the duodenum as the pathogenic center. J Gastroenterol 2019; 54 (4): 305-11.
- Leech B, Schloss J, Steel A. Treatment Interventions for the Management of Intestinal Permeability: A Cross-Sectional Survey of Complementary and Integrative Medicine Practitioners. J Altern Complement Med 2019; 25 (6): 623-36.
- Leech B, McIntyre E, Steel A, Sibbritt D. Risk factors associated with intestinal permeability in an adult population: A systematic review. Int J Clin Pract 2019: e13385. doi: 10.1111/ijcp.13385
- Sturniolo G.C, Di Leo V, Ferronato A et al. Zinc supplementation tightens ‘leaky gut’ in Crohn's disease. Inflamm Bowel Dis 2001; 7 (2): 94-8.
- Sturniolo G.C, Fries W, Mazzon E et al. Effect of zinc supplementation on intestinal permeability in experimental colitis. J Lab Clin Med 2002; 139 (5): 311-5.
- Zhou Q, Verne M.L, Fields J.Z et al. Randomised placebo-controlled trial of dietary glutamine supplements for postinfectious irritable bowel syndrome. Gut 2019; 68 (6): 996-1002.
- Bertrand J, Ghouzali I, Guérin C et al. Glutamine Restores Tight Junction Protein Claudin-1 Expression in Colonic Mucosa of Patients With Diarrhea-Predominant Irritable Bowel Syndrome. JPEN J Parenter Enteral Nutr 2016; 40 (8): 1170-6.
- Kelly C.P, Green P.H, Murray J.A et al. Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: a randomised placebo-controlled study. Aliment Pharmacol Ther 2013; 37 (2): 252-62.
- Naito Y, Yoshikawa T. Rebamipide: a gastrointestinal protective drug with pleiotropic activities. Expert Rev Gastroenterol Hepatol 2010; 4 (3): 261-70.
- Song D.U, Ryu M.H, Chay K.O et al. Effect of rebamipide on the glycosaminoglycan content of the ulcerated rat stomach. Fundam Clin Pharmacol 1998; 12 (5): 546-52.
- Suzuki T, Yoshida N, Nakabe N et al. Prophylactic effect of rebamipide on aspirin-induced gastric lesions and disruption of tight junctional protein zonula occludens-1 distribution. J Pharmacol Sci 2008; 106 (3): 469-77.
- Tarnawski A.S, Chai J, Pai R, Chiou S.K. Rebamipide activates genes encoding angiogenic growth factors and Cox2 and stimulates angiogenesis: a key to its ulcer healing action? Dig Dis Sci 2004; 49 (2): 202-9.
- Jaafar M.H, Safi S.Z, Tan M.P et al. Efficacy of Rebamipide in Organic and Functional Dyspepsia: A Systematic Review and Meta-Analysis. Dig Dis Sci 2018; 63 (5): 1250-60.
- Miwa H, Osada T, Nagahara A et al. Effect of a gastro-protective agent, rebamipide, on symptom improvement in patients with functional dyspepsia: a double-blind placebo-controlled study in Japan. J Gastroenterol Hepatol 2006; 21 (12): 1826-31.
- Matysiak-Budnik T, Heyman M, Mégraud F. Review article: rebamipide and the digestive epithelial barrier. Aliment Pharmacol Ther 2003; 18 (Suppl. 1): 55-62.
- Pittayanon R, Leelakusolvong S, Vilaichone R.K et al. Thailand Dyspepsia Guidelines: 2018. J Neurogastroenterol Motil 2019; 25 (1): 15-26.
Supplementary files
